The Fast Money traders take a look at today's biggest market movers.» Read More
Lehman Brothers reported a record $3.93 billion quarterly loss, while top economists debated over the GSE takeover of Fannie Mae and Freddie Mac. Following are today's top videos:
Andrew Littlefair says it's only a matter of time before American cars are running on this plentiful domestic natural resource.
The blogging CEO is not a new creature in the internet landscape – some members of the blogging CEO club have diligently posted since the days of the dot-com bust.
At the Thomson Reuters/BioCentury investment conference some hedge fund guy, who I'd never met before and who will remain unidentified, whispered in my ear that there's gonna be a bidding war for ImClone Systems.
Lehman's shares plunge as much as 43 percent of its value while Steve Jobs introduces a new line of colorful and extra-thin Apple iPods. Following are today's top videos:
When the majors need to cut costs, they turn to Covance.
The Lehman Brothers CEO missed every chance he had to save his firm.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
But are they worth buying? Cramer asked National Semiconductor CEO Brian Halla for an answer.
John McCain becomes the official Republican presidential nominee while strategists tell investors to take advantage of the gloomy economy by buying the market. Following are today's top videos:
Settlement negotiations between lawyers representing former AIG chief Hank Greenberg and the New York Attorney General are at a stalemate.
Pimco's bond guru was wrong about a recent offering, the bank says.
"There is no bull market!" declares Bill Gross while GOP vice-presidential nominee Sarah Palin's powerful speech at the Republican National Convention on Wednesday night impresses Republicans and many swing voters. Following are today's top videos:
Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.
A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.
Andrew Puzder got off the plane only a couple of hours before I sat down to talk to him. Still adjusting to the humidity of the Singapore climate, the CEO was in good spirits. Casually dressed for the interview, you would never have guessed he was a high powered corporate attorney. Puzder admits he never imagined he would end up in the fast food business.
The chief executive explains why his company took such a hit after Wednesday's earnings call.
Economic worries are still hanging over the market, and CNBC went straight to the top to get some answers.
In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).
There's an interesting theory when it comes to the SUV market. It goes like this: now is the best time to buy an SUV because the used market has bottomed out and prices will soon start going up. The more I've heard this, the more I've talked with dealers. And you know what their reaction is? A good laugh.